Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation

Blood

Volumn 117, Issue 2, 2011, Pages 412-418

  Galper, Shira L ^a,b   Yu, James B ^b   Mauch, Peter M ^a   Strasser, Jon F ^a,e   Silver, Barbara ^a   LaCasce, Ann ^a   Marcus, Karen J ^a   Stevenson, Mary Ann ^c   Chen, Ming Hui ^a,d   Ng, Andrea K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HELEN F GRAHAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; CANCER RADIOTHERAPY; CARDIOVASCULAR PROCEDURES; CARDIOVASCULAR RISK; CHILD; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART DISEASE; HODGKIN DISEASE; HUMAN; INCIDENCE; IRRADIATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERICARDIAL DISEASE; PREDICTOR VARIABLE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VALVULAR HEART DISEASE;

EID: 78751511293     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-291328     Document Type: Article

References (32)

1. Leukemia and Lymphoma Society. Hodgkin Lymphoma Facts and Statistics. http://www.leukemialymphoma.org/all-page.adp?item-id=8312. Accessed October 11, 2010.
2. Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. New Engl J Med. 2007;357(19):1916-1927.
3. Allemani C, Sant M, De Angelis R, Marcos-Gragera R, Coebergh JW. Hodgkin disease survival in Europe and the U.S.: prognostic significance of morphologic groups. Cancer. 2006;107(2):352-360.
4. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. [see comment]. J Clin Oncol. 1993;11(7):1208-1215.
5. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206-214.
6. Henry-Amar M, Hyatt M, Meerwaldt JH. Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. Int J Radiat Oncol Biol Phys. 1990(19):1155-1157.
7. Vaughan Hudson B, Vaughan Hudson G, Linch DC, Anderson L. Late mortality in young BNLI patients cured of Hodgkin's disease. Ann Oncol. 1994;5(Suppl 2):65-66. (Pubitemid 24061322)
8. Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am. 1995;1(1):33-42.
9. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol. 1997;8(Suppl 1):115-118.
10. Boivin JF, Hutchison GB, Lubin JH, Mauch P. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer. 1992;69(5):1241-1247.
11. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002;20(8):2101-2108.
12. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21(18):3431-3439.
13. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004;22(15):3139-3148.
14. Glanzmann C, Huguenin P, Lutolf UM, Maire R, Jenni R, Gumppenberg V. Cardiac lesions after mediastinal irradiation for Hodgkin's disease. Radiother Oncol. 1994;30(1):43-54. (Pubitemid 24056906)
15. Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol. 1998;46(1):51-62. (Pubitemid 28072859)
16. Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42(4):743-749. (Pubitemid 37000197)
17. Perrault DJ, Levy M, Herman JD, et al. Echocardiographic abnormalities following cardiac radiation. J Clin Oncol. 1985;3(4):546-551. (Pubitemid 15111403)
18. Lund MB, Ihlen H, Voss BM, et al. Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study. Heart. 1996;75(6):591-595.
19. Gustavsson A, Eskilsson J, Landberg T, et al. Late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease. Ann Oncol. 1990;1(5):355-363.
20. Pohjola-Sintonen S, Totterman KJ, Salmo M, Siltanen P. Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin's disease. Cancer. 1987;60(1):31-37. (Pubitemid 17083547)
21. Kreuser ED, Voller H, Behles C, et al. Evaluation of late cardiotoxicity with pulsed Doppler echocardiography in patients treated for Hodgkin's disease. Br J Haematol. 1993;84(4):615-622. (Pubitemid 23248052)
22. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831-2837.
23. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878- 1886.
24. Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49(8):1486-1493.
25. National Center for Health Statistics. 2000 National Hospital Discharge Survery (NHDS). http://www.cdc.gov/nchs/nhds.htm. Accessed June 1, 2006.
26. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. (Pubitemid 29126745)
27. Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata Journal. 2004;4:103-112.
28. Breslow NE, Day NE. Statistical Methods in Cancer Research: Vol II. The Design and Analysis of Cohort Studies. Lyon, France: WHO International Agency for Research on Cancer; 1987.
29. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 1993;270(16):1949- 1955.
30. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol. 2001;19(1):191-196.
31. Aviles A, Neri N, Nambo JM, Huerta-Guzman J, Talavera A, Cleto S. Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy. Leuk Lymphoma. 2005;46(7):1023-1028.
32. Steinherz LJ. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1997;126(10):827 [author reply 827-828].